Novavax(US:NVAX) ZACKS·2025-05-02 22:50Company Performance - Novavax (NVAX) closed at $6.41, unchanged from the previous session, lagging behind the S&P 500's 1.47% gain [1] - Over the past month, Novavax shares have increased by 14.46%, while the Medical sector has decreased by 2.95% and the S&P 500 by 0.47% [1] Earnings Forecast - Novavax is expected to report an EPS of $0.19 on May 8, 2025, representing a 118.1% increase year-over-year [2] - Revenue is forecasted to be $71.84 million, indicating a 23.47% decline compared to the same quarter of the previous year [2] - For the entire year, earnings are projected at $0.63 per share and revenue at $536.24 million, reflecting changes of +151.22% and -21.39% respectively compared to the previous year [3] Analyst Estimates - Recent adjustments to analyst estimates for Novavax indicate changing business trends, with upward revisions suggesting positive sentiment towards the company's operations [4] - The Zacks Rank system, which incorporates these estimate changes, currently ranks Novavax at 3 (Hold) [6] Valuation Metrics - Novavax has a Forward P/E ratio of 10.2, which is lower than the industry average of 17.32, indicating it is trading at a discount [7] - The company has a PEG ratio of 0.24, significantly below the industry average of 1.34, suggesting favorable valuation relative to expected earnings growth [8] Industry Context - The Medical - Biomedical and Genetics industry, which includes Novavax, holds a Zacks Industry Rank of 84, placing it in the top 35% of over 250 industries [9] - Research indicates that industries in the top 50% outperform those in the bottom half by a factor of 2 to 1 [9]